The Tufts Center for the Study of Drug Development (Tufts CSDD) is conducting a study on investigative site perspectives and burden associated with Direct-to-Patient (DTP) shipment of study treatments and supplies.
Researchers at Tufts CSDD at the Tufts University School of Medicine, in collaboration with Global Clinical Supplies Group (GCSG), a professional organization of global clinical supplies professionals, are conducting an academic survey to increase understanding of investigative site personnel experiences with the shipment of Investigational Products/Study Treatments to trial participants at their homes—also known as Direct-to-Patient (DtP) shipments of study drug. Your feedback is invaluable in helping to identify pain points and improvement areas.
Please take a few minutes to take survey. In appreciation for your participation, the Tufts CSDD research team will share with you a summary of results when the research concludes. Start the survey: https://tufts.qualtrics.com/jfe/form/SV_2bm7lW1vt6zl53g
Thank you in advance for your participation in this important research effort!
Tecentriq Falls Short in Phase III Trial in Post-Surgery Triple-Negative Breast Cancer Patients
February 6th 2025In the ALEXANDRA/IMpassion030 trial, Tecentriq (atezolizumab) added to postoperative chemotherapy was not found to improve treatment outcomes for patients with high-risk early-stage triple-negative breast cancer.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.